13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-04-23 Event 2026-04-16 Intent: UNCLEAR SEC 0001875620-26-000007 →

Sands Capital Life Sciences Pulse Fund II, L.P. Alamar Biosciences, Inc. ALMR

Stake: 6.30% Shares: 4,230,926 CUSIP: 010911105 Class: Common Stock, par value $0.0001 per share
AI Analyst Brief conf: low
Sands Capital Life Sciences Pulse Fund II files a 13D on ALMR with 4.23M shares, notable because this is the fund's first 13D/G filing and lands on an issuer that has already attracted 2 activist filings in the past 90 days — suggesting ALMR is under coordinated pressure despite no disclosed purpose in this extract.

Item 4 — Purpose of Transaction

The Reporting Persons acquired and hold the Common Stock for investment purposes in the ordinary course of Sands Pulse Fund II's investment activities. Subject to applicable legal requirements or contractual restrictions, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions depending on their evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer and/or members of the board of directors of the Issuer, to discuss matters regarding the Issuer including but not limited to its operations and strategic direction. Ian Ratcliffe, who serves on the Issuer's board of directors, is an Executive Managing Partner of the Life Sciences Pulse strategy and an Executive Managing Director of Sands Capital Alternatives, and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director. Except as set forth in this Schedule 13D, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons reserve the right to formulate such plans or proposals in the future.

Cross-References

Insider Activity (last 365d)
86 transactions
12 buys · 0 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
2 filings by this filer
1 other filing in the data moat
Short Interest · settle 2026-07-15
DTC 7.58
2,245,722 shares short · -19.5% vs prior

Post-Filing Returns · since 2026-04-16 on ALMR

+1 day
0.0%
+5 days
+5.6%
+30 days
+14.7%
+60 days
+14.7%
+90 days
+18.8%
+180 days

Anchor price 22.00 on closest trading day on/after 2026-04-16. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner C 185,163
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 4,588,364
2026-04-20 Chambers Rebecca director J 140,612 $7.60 $1.07M
2026-04-20 Witney Frank director J 49,627 $0.59 $29K
2026-04-20 White Timothy Ogden officer J 454,583
2026-04-20 Chen Shiping director, officer C 320,511
2026-04-20 Luo Yuling director, officer C 1,386,746
2026-04-20 McAnear Justin J. officer Award 37,220
2026-04-20 Naclerio Nicholas director C 4,588,364
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 922,152
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner J 5,510,516
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 346,020
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 271,782
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner Buy 235,294 $17.00 $4.00M
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 3,194,377
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 2,862,507
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 2,094,266
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C 5,037,783
2026-04-20 Illumina Innovation Fund II GP, L.L.C. 10%+ owner C
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner C 6,881,410
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner C 1,605,645
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner C 1,922,329
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner J 185,163
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner J 6,881,410
2026-04-20 Qiming Corporate GP VI, Ltd. 10%+ owner J 1,605,645
Showing 25 of 86

Other 13D/G Filings on Alamar Biosciences, Inc.

FiledFormFilerStakeShares
2026-07-07 SCHEDULE 13D/A Sands Capital Life Sciences Pulse Fund II, L.P. 6.10% 4,230,926 view →
2026-07-02 SCHEDULE 13G SHERPA HEALTHCARE FUND II, L.P. view →
2026-04-23 SCHEDULE 13D Illumina Innovation Fund II, L.P. 9.60% 5,856,536 view →

Other Filings by Sands Capital Life Sciences Pulse Fund II, L.P.

FiledFormIssuerStakeShares
2026-07-07 SCHEDULE 13D/A Alamar Biosciences, Inc. ALMR 6.10% 4,230,926 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →